[go: up one dir, main page]

PE20171799A1 - Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada - Google Patents

Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada

Info

Publication number
PE20171799A1
PE20171799A1 PE2017001626A PE2017001626A PE20171799A1 PE 20171799 A1 PE20171799 A1 PE 20171799A1 PE 2017001626 A PE2017001626 A PE 2017001626A PE 2017001626 A PE2017001626 A PE 2017001626A PE 20171799 A1 PE20171799 A1 PE 20171799A1
Authority
PE
Peru
Prior art keywords
sulfatase
acetylgalactosamine
highly active
formulation including
active human
Prior art date
Application number
PE2017001626A
Other languages
English (en)
Inventor
Vish Koppaka
Michel Claude Vellard
Augustus O Okhamafe
Kidisti Araya
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20171799A1 publication Critical patent/PE20171799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un metodo de purificacion de una enzima N-acetilgalactosamina-6-sulfatasa (GALNS) humana recombinante. Dicha GALNS es util en el diagnostico, profilaxis o tratamiento de enfermedades y condiciones, tales como las enfermedades por almacenamiento lisosomal que son ocasionadas por o estan asociadas con una deficiencia en la enzima GALNS, por ejemplo, la Mucopolisacaridosis IVa (MPS IVa o sindrome de Morquio A)
PE2017001626A 2010-07-22 2011-07-22 Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada PE20171799A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36671410P 2010-07-22 2010-07-22

Publications (1)

Publication Number Publication Date
PE20171799A1 true PE20171799A1 (es) 2017-12-28

Family

ID=44543776

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2017001626A PE20171799A1 (es) 2010-07-22 2011-07-22 Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
PE2017001625A PE20171798A1 (es) 2010-07-22 2011-07-22 Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
PE2013000110A PE20131140A1 (es) 2010-07-22 2011-07-22 Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2017001625A PE20171798A1 (es) 2010-07-22 2011-07-22 Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
PE2013000110A PE20131140A1 (es) 2010-07-22 2011-07-22 Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Country Status (28)

Country Link
US (3) US8765437B2 (es)
EP (1) EP2595650B1 (es)
JP (2) JP6030553B2 (es)
KR (2) KR101949906B1 (es)
CN (1) CN103037895B (es)
AR (2) AR082319A1 (es)
AU (1) AU2011280937B2 (es)
BR (1) BR112013001558B1 (es)
CA (2) CA2805673C (es)
CL (2) CL2013000219A1 (es)
CY (1) CY1118934T1 (es)
DK (1) DK2595650T3 (es)
ES (1) ES2616263T3 (es)
HR (1) HRP20170245T1 (es)
HU (1) HUE033163T2 (es)
IL (2) IL224125B (es)
LT (1) LT2595650T (es)
MX (1) MX341838B (es)
PE (3) PE20171799A1 (es)
PL (1) PL2595650T3 (es)
PT (1) PT2595650T (es)
RS (1) RS55669B1 (es)
RU (1) RU2607376C2 (es)
SG (1) SG187580A1 (es)
SI (1) SI2595650T1 (es)
SM (2) SMT201700106T1 (es)
WO (1) WO2012012718A2 (es)
ZA (1) ZA201300286B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009205978B2 (en) * 2008-01-18 2014-04-10 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
US20130202633A1 (en) * 2012-02-07 2013-08-08 Saint Louis University, A Non-Profit Organization Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US11529397B2 (en) 2018-01-22 2022-12-20 Saint Louis University Method of treating mucopolysaccharidosis type IVA
EP2970380B1 (en) * 2013-03-13 2018-05-02 Shire Human Genetic Therapies, Inc. Method of characterizing lysosomal enzymes
PL2968494T3 (pl) 2013-03-13 2019-04-30 Seattle Genetics Inc Filtracja z węglem aktywnym do oczyszczania benzodiazepinowych ADC
BR112015028605A8 (pt) 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
WO2014201220A1 (en) * 2013-06-12 2014-12-18 The Board Of Trustees Of The University Of Illinois Methods for detecting prostate cancer
KR101894762B1 (ko) 2013-07-12 2018-09-05 이엠디 밀리포어 코포레이션 표적 단백질을 함유하는 샘플로부터 활성탄을 사용하여 바이러스 제거를 결정하는 방법
US20170191041A1 (en) * 2014-07-11 2017-07-06 Biostrategies LC Materials and methods for treating disorders associated with sulfatase enzymes
US10472615B2 (en) 2016-01-21 2019-11-12 Saint Louis University Reduced immunogenic proteins for lysosomal storage disorders
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
WO2019045149A1 (en) * 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
WO2021216460A1 (en) * 2020-04-19 2021-10-28 Figene, Llc Gene modified fibroblasts for therapeutic applications
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202403043A (zh) * 2022-03-18 2024-01-16 美商健臻公司 重組人類酸性鞘磷脂酶醫藥組合物及方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
JPS62122588A (ja) 1985-11-22 1987-06-03 Taiyo Fishery Co Ltd 純コンドロイチナ−ゼの製造法
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
RU2195492C2 (ru) * 2000-09-04 2002-12-27 Институт физиологии Коми научного центра Уральского отделения РАН Способ получения пектолитического ферментного препарата
WO2002074969A2 (en) 2001-01-26 2002-09-26 University Of Lausanne Matrix attachment regions and methods for use thereof
KR101035043B1 (ko) * 2002-07-01 2011-05-19 아르키온 라이프 사이언씨즈 엘엘씨 글루코사민 및 ｎ-아세틸글루코사민의 제조를 위한 물질및 공정
PT1592786E (pt) 2003-02-11 2012-01-19 Shire Human Genetic Therapies Diagnóstico e tratamento da deficiência de múltiplas sulfatases e outras utilizando uma enzima geradora de formilglicina (fge)
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
NZ555206A (en) * 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080231439A1 (en) 2007-03-22 2008-09-25 Inventec Corporation Activity Detection Circuit for a Storage Device
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
AU2009205978B2 (en) * 2008-01-18 2014-04-10 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
SMT201700106B (it) 2017-03-08
AR082319A1 (es) 2012-11-28
CA2805673C (en) 2022-04-05
BR112013001558B1 (pt) 2022-08-16
EP2595650B1 (en) 2016-11-16
WO2012012718A3 (en) 2012-04-05
SG187580A1 (en) 2013-03-28
RU2607376C2 (ru) 2017-01-10
WO2012012718A2 (en) 2012-01-26
MX2013000908A (es) 2013-07-05
IL260282B (en) 2020-05-31
JP2016178950A (ja) 2016-10-13
RS55669B1 (sr) 2017-06-30
JP2013532986A (ja) 2013-08-22
SI2595650T1 (sl) 2017-04-26
KR101949906B1 (ko) 2019-04-22
AU2011280937B2 (en) 2016-06-09
DK2595650T3 (en) 2017-02-27
CN103037895A (zh) 2013-04-10
PE20171798A1 (es) 2017-12-28
JP6030553B2 (ja) 2016-11-24
CY1118934T1 (el) 2018-01-10
CL2013000219A1 (es) 2014-07-11
HRP20170245T1 (hr) 2017-04-21
LT2595650T (lt) 2017-03-10
PE20131140A1 (es) 2013-10-17
RU2013107765A (ru) 2014-08-27
ES2616263T3 (es) 2017-06-12
ZA201300286B (en) 2014-03-26
HUE033163T2 (en) 2017-11-28
AU2011280937A1 (en) 2013-01-31
PL2595650T3 (pl) 2017-06-30
BR112013001558A2 (pt) 2020-08-04
EP2595650A2 (en) 2013-05-29
PT2595650T (pt) 2017-02-22
KR20130105605A (ko) 2013-09-25
US20140341878A1 (en) 2014-11-20
US20120189605A1 (en) 2012-07-26
US20160186149A1 (en) 2016-06-30
CA2805673A1 (en) 2012-01-26
MX341838B (es) 2016-09-05
AR119552A2 (es) 2021-12-29
US8940513B2 (en) 2015-01-27
CL2017000498A1 (es) 2017-11-24
KR20150038715A (ko) 2015-04-08
KR101598897B1 (ko) 2016-03-03
CA3146151A1 (en) 2012-01-26
CN103037895B (zh) 2016-11-09
US9567572B2 (en) 2017-02-14
SMT201700106T1 (it) 2017-03-08
IL224125B (en) 2019-02-28
IL260282A (en) 2018-07-31
US8765437B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
PE20171799A1 (es) Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
BR112015019997A2 (pt) Métodos de sacarificar e fermentar um material celulósico
MX2010007846A (es) Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
MX2013006234A (es) Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero.
EP4032538A3 (en) Methods and products for in vivo enzyme profiling
MX366155B (es) Celulas para producir iduronato-2-sulfatasa recombinante.
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
BR112013033581A2 (pt) Composições de limpeza que compreendem variantes da amilase com referencia a uma listagem de sequencia
MX349992B (es) Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
MX2013014307A (es) Metodo de tratamiento de celulas madre mesenquinales y su uso en el tratamiento de enfermedades asociadas a estres oxidativo.
WO2013188313A3 (en) Fungal xylanases and xylosidases
EP2951286A4 (en) RECOMBINANT MICROORGANISMS WITH NADPH-DEPENDENT ENZYMES AND METHOD FOR THE PRODUCTION THEREOF
AR106117A1 (es) Método de concentración de proteína en polvo de grano
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
AR118157A2 (es) Una enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante, composición y sus usos
WO2012103263A3 (en) Compositions and methods for malate and fumarate production
DOP2012000039A (es) Inhibidores de catepsina c
NZ603807A (en) A heterogeneous inseminate system
EA201500018A1 (ru) Ферментативное восстановление
EA201500174A1 (ru) Способ изготовления рекомбинантной тирозиназы человека
CL2012000966A1 (es) Procedimiento para producir fibras de celulosa, que comprende la asociacion de al menos un tratamiento enzimatico con al menos una etapa acida, en donde en el tratamiento enzimatico las enzimas hidroliticas son seleccionadas del grupo que consta de celulasas, xilanasas y mezclas de las mismas.